Clinical trials: Tislelizumab, open to volunteers
Non Small Cell Lung Cancer
Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC
This study aims to investigate the efficacy and safety of fecal microbiota transplantation (FMT) as a treatment for non-small cell lung cancer (NSCLC) patients whose disease has progressed after immune checkpoint inhibitor (ICI)…
- Trial name
- FMT-LUNG (NCT07432984)
- Testing
- Tislelizumab, Fecal Microbiota Transplant(FMT)
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Se-Hoon Lee
NSCLC Associated With Leptomeningeal Metastases
Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC
This is a prospective, single-arm, open clinical study, which was designed to evaluate the efficacy and safety of an immune checkpoint inhibitor combined with pemetrexed intrathecal injection in the treatment of patients with…
- Trial name
- NCT06132698
- Testing
- Tislelizumab or pembrolizumab, pemetrexed
- Where
- China
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- West China Hospital
Nasopharyngeal Cancinoma (NPC), SBRT
SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy
This study is a single-arm, open-label, prospective, and exploratory investigation aimed at examining the short-term efficacy, specifically the objective response rate (ORR), of SBRT combined with Nimotuzumab followed by…
- Conditions
- Nasopharyngeal Cancinoma (NPC), SBRT, Immunotherapy
- Trial name
- NCT06676722
- Testing
- SBRT combined with Nimotuzumab followed by Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Xiamen University
NSCLC Stage IIIB, NSCLC Stage IIIC
Clinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLC
This is an observational study evaluating the clinical characteristics, treatment patterns, and clinical outcomes in Stage III (cTNM-IIIB/IIIC) Non-Small Cell Lung Cancer.Patients meeting inclusion and exclusion criteria were…
- Trial name
- NCT06829641
- Testing
- Tislelizumab Combined with Chemotherapy,
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- West China Hospital
Gastric, Colorectal Adenocarcinoma
Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations
Objective of this study to evaluate 1-year disease-free survival in patients with dMMR/MSI-H or POLE/POLD1 gene mutations with gastric or esophagus-gastric junctional adenocarcinoma or colorectal adenocarcinoma after…
- Trial name
- NCT06118658
- Testing
- tislelizumab
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- China Medical University, China